510(k) device
Saffron Fixation System
Coloplast A/S · Fixation, Non-Absorbable Or Absorbable, For Pelvic Use (PBQ, Class II) · First FDA decision Jun 10, 2022, newest Jun 10, 2022Pelvic organ prolapse
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Saffron"
MAUDE reports
0
Brand "Saffron", since 2015
PubMed studies
2,573
Mentioning "Saffron"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Saffron Fixation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Saffron", any status and sponsor, newest update first.
No registered device study names "Saffron".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Saffron", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PBQ
65 reports: 48 malfunction, 16 injury, 0 death
Newest reports for this brand
- SAFFRON ANCHORInjury
2125050-2026-00774 · Received May 8, 2026
Device type: Fixation, Non-Absorbable Or Absorbable, For Pelvic Use (PBQ)
Device problem as coded: Device Dislodged or Dislocated
Patient problem as coded: Prolapse
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Saffron"[tiab]. The summary above synthesizes these.
- The Effects of Crocus sativus (Saffron) on ADHD: A Systematic Review.
Seyedi-Sahebari S, Farhang S, Araj-Khodaei M, et al. · J Atten Disord · 2024Systematic Review, Research Support, Non-U.S. Gov't
- Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials.
Shafiee A, Jafarabady K, Seighali N, et al. · Nutr Rev · 2025Meta-Analysis
- Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action.
Lopresti AL, Drummond PD · Hum Psychopharmacol · 2014Systematic Review
- Effectivity of Saffron Extract (Saffr'Activ) on Treatment for Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD): A Clinical Effectivity Study.
Blasco-Fontecilla H, Moyano-Ramírez E, Méndez-González O, et al. · Nutrients · 2022Clinical Trial
- Saffron (Crocus sativus L.): A Source of Nutrients for Health and for the Treatment of Neuropsychiatric and Age-Related Diseases.
El Midaoui A, Ghzaiel I, Vervandier-Fasseur D, et al. · Nutrients · 2022Review
- Exploring the Potential of Saffron as a Therapeutic Agent in Depression Treatment: A Comparative Review.
Chauhan S, Tiwari A, Verma A, et al. · Yale J Biol Med · 2024Review, Comparative Study
- Saffron and its major constituents against neurodegenerative diseases: A mechanistic review.
Abdian S, Fakhri S, Moradi SZ, et al. · Phytomedicine · 2024Systematic Review
- New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms.
Han S, Cao Y, Wu X, et al. · Phytother Res · 2024Systematic Review, Meta-Analysis
- Maximizing saffron apocarotenoid production in varied tomato fruit carotenoid contexts.
Lobato-Gómez M, Drapal M, Fernández-Muñoz R, et al. · Plant J · 2024Research Support, Non-U.S. Gov't
- Saffron: Chemical Composition and Neuroprotective Activity.
Maggi MA, Bisti S, Picco C · Molecules · 2020
- Saffron improves the efficacy of immunotherapy for colorectal cancer through the IL-17 signaling pathway.
Feng S, Li S, Wu Z, et al. · J Ethnopharmacol · 2025
- Exploring the viral landscape of saffron through metatranscriptomic analysis.
Martínez-Fajardo C, Navarro-Simarro P, Morote L, et al. · Virus Res · 2024Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code PBQ.
- ApyxEscala Medical · 510(k) 2023
- MenditEscala Medical, Ltd. · 510(k) 2026
- NeuGuidePop Medical Solutions · 510(k) 2016
- Endofast Reliant Scp, Endofast Reliant LapIbi Israel Biomedical Innovations , Ltd. · 510(k) 2013
- AnchorsureNeomedic International S.L. · 510(k) 2012
- Gynecare Prolene Fastener SystemETHICON, Inc. · 510(k) 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.